Articles

A study at AAD VMX 2021 presented data on possible association between sex, skin cancer medication, and dermatologic adverse events. 

Relation Between Skin Cancer Medication and Dermatologic Adverse Events

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

FDA Grants Orphan Drug Status to ITIL-168 for Melanoma

Videos

In this video interview, Melissa Stenstrom, MD, discusses how physicians can promote the use of sun protection and regular skin cancer screenings to help prevent skin cancer among their patients.

Preventing Skin Cancer Through Sun Protection

A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge. 

AAD Finds One Third of American’s Fail Quiz on Skin Cancer

Artificial intelligence diagnostics are less accurate on skin of color than light skin, even when trained on equal numbers of images.

AI Diagnostics Fall Short in Skin of Color 

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

Tips to Improve High-Risk Skin Cancer Management

More detailed tumor classifications, patient data advance surveillance strategies for the high-risk patient population.

Step up Surveillance Strategies for Skin Cancer

Podcasts

With the summer months quickly  approaching, we’re discussing the importance of skin cancer screenings, as well as encouraging regular sun protection usage among patients. This episode also touches on the role of telemedicine in skin cancer screenings, top product recommendations for sun protection and tips on managing patient expectations if the patient is diagnosed with skin cancer.  


The Cutaneous Connection: Episode 22- The Role of Sun Protection in Skin Cancer Prevention

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

Combos Lead Excitement in BRAF+ Melanoma, but More Pain Points are Ready to be Tackled

The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.